Cargando…

Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies

BACKGROUND: The studies IMvigor 210 cohort 2 and IMvigor211 evaluated the efficacy of atezolizumab in patients with locally advanced or metastatic urothelial cancer (mUC) upon progression to platinum-based chemotherapy worldwide. Yet, the real impact of this drug in specific geographical regions is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sotelo, M., Alonso-Gordoa, T., Gajate, P., Gallardo, E., Morales-Barrera, R., Pérez-Gracia, J. L., Puente, J., Sánchez, P., Castellano, D., Durán, I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979625/ https://www.ncbi.nlm.nih.gov/pubmed/32897497 http://dx.doi.org/10.1007/s12094-020-02482-9

Ejemplares similares

Clinical, molecular, and immune correlates of the Immunotherapy Response Score in patients with advanced urothelial carcinoma under atezolizumab monotherapy: analysis of the phase II IMvigor210 trial
por: Ferreiro-Pantín, M., et al.
Publicado: (2023)

Role of atezolizumab therapy combined with platinum-based chemotherapy in untreated metastatic urothelial carcinoma – The new landscapes (IMvigor130 trial)
por: Misra, Ankit
Publicado: (2021)

Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer
por: Aydin, Ahmet Murat, et al.
Publicado: (2017)

De Novo Myasthenia Gravis Induced by Atezolizumab in a Patient with Urothelial Carcinoma
por: Thakolwiboon, Smathorn, et al.
Publicado: (2019)

Emerging use of everolimus in the treatment of neuroendocrine tumors
por: Gajate, Pablo, et al.
Publicado: (2017)

Atezolizumab in Patients with Pretreated Urothelial Cancer: a Korean Single-Center, Retrospective Study
por: Hur, Joon Young, et al.
Publicado: (2019)

Safety and efficacy of atezolizumab in the treatment of cancers: a systematic review and pooled-analysis
por: Tie, Yan, et al.
Publicado: (2019)

Translating new data to the daily practice in second line treatment of renal cell carcinoma: The role of tumor growth rate
por: Grande, Enrique, et al.
Publicado: (2017)

Skin autoimmunity might be associated with increased efficacy of atezolizumab in metastatic urothelial carcinoma: a case report
por: Rkman, Deni, et al.
Publicado: (2019)

Pericardial malignant infiltration as the cause of sudden death of a patient with metastatic urothelial carcinoma treated with atezolizumab
por: Palacka, Patrik, et al.
Publicado: (2022)

Atezolizumab for the treatment of advanced recurrent basal cell carcinoma and urothelial carcinoma of bladder: a case report
por: Küronya, Zsófia, et al.
Publicado: (2022)

Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma
por: Mar, Nataliya, et al.
Publicado: (2023)

Genomic Landscape of Vinflunine Response in Metastatic Urothelial Cancer
por: Bernardini, Alejandra, et al.
Publicado: (2022)

FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy
por: Suzman, Daniel L., et al.
Publicado: (2018)

FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum‐Containing Chemotherapy
por: Ning, Yang‐Min, et al.
Publicado: (2017)

Assessing the impact of organ-specific lesion dynamics on survival in patients with recurrent urothelial carcinoma treated with atezolizumab or chemotherapy
por: Kerioui, M., et al.
Publicado: (2021)

Draft Genome Sequences of Clinical Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Strain APS211 and Its Daptomycin-Susceptible Progenitor APS210
por: Cameron, David R., et al.
Publicado: (2015)

Practice change in the management of metastatic urothelial carcinoma after ASCO 2020
por: Gajate, Pablo, et al.
Publicado: (2020)

Properties of $^{211}_{85}$At$_{126}$ as observed in the decay of $^{211}$Rn
por: Astner, G
Publicado: (1972)

Memorandum: future of R-211
por: Favart, D, et al.
Publicado: (1982)

Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis
por: Liu, Xiaoyan, et al.
Publicado: (2022)

Hypoxia-regulated MicroRNA-210 Overexpression is Associated with Tumor Development and Progression in Upper Tract Urothelial Carcinoma
por: Ke, Hung-Lung, et al.
Publicado: (2017)

Novel Tyrosine Kinase Targets in Urothelial Carcinoma
por: Torres-Jiménez, Javier, et al.
Publicado: (2021)

Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
por: Grande, Enrique, et al.
Publicado: (2023)

Human dosimetry of free (211)At and meta-[(211)At]astatobenzylguanidine ((211)At-MABG) estimated using preclinical biodistribution from normal mice
por: Ukon, Naoyuki, et al.
Publicado: (2020)

(226)Ra, (210)Pb, (210)Bi and (210)Po deposition and removal from surfaces and liquids
por: Wójcik, M., et al.
Publicado: (2012)

Tuna Species Substitution in the Spanish Commercial Chain: A Knock-On Effect
por: Gordoa, Ana, et al.
Publicado: (2017)

Disease Control with Prior Platinum-based Chemotherapy Is Prognostic for Survival in Patients with Metastatic Urothelial Cancer Treated with Atezolizumab in Real-world Practice
por: Mencinger, Marina, et al.
Publicado: (2021)

A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
por: Jang, H. Josh, et al.
Publicado: (2023)

The decay of $^{210}_{86}$Rn$_{124}$ to levels in $^{210}_{85}$At$_{125}$
por: Jonson, B, et al.
Publicado: (1972)

The polish wheat (Triticum polonicum L.) TpSnRK2.10 and TpSnRK2.11 meditate the accumulation and the distribution of cd and Fe in transgenic Arabidopsis plants
por: Wang, Ruijiao, et al.
Publicado: (2019)

Preclinical Development of [(211)At]meta- astatobenzylguanidine ([(211)At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
por: Batra, Vandana, et al.
Publicado: (2022)

Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis
por: Parisi, Alessandro, et al.
Publicado: (2019)

Transition probabilities of low-lying excited states in 210Po and 210Pb
por: Georgiev, Georgi, et al.
Publicado: (2022)

Baseline risk factors associated with immune related adverse events and atezolizumab
por: Madjar, Katrin, et al.
Publicado: (2023)

Charge radii and electromagnetic moments of $^{195–211}$At
por: Cubiss, J G, et al.
Publicado: (2018)

Determination of the mean aerosol residence times in the atmosphere and additional (210)Po input on the base of simultaneous determination of (7)Be, (22)Na, (210)Pb, (210)Bi and (210)Po in urban air
por: Długosz-Lisiecka, Magdalena, et al.
Publicado: (2012)

Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
por: Ahmed, Faiza, et al.
Publicado: (2021)

Radionuclides ((210)Po and (210)Pb) and Some Heavy Metals in Fish and Sediments in Lake Bafa, Turkey, and the Contribution of (210)Po to the Radiation Dose
por: Manav, Ramazan, et al.
Publicado: (2016)

Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC)
por: Powles, Thomas, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_lboqcjla2ig0d0io7e20pm4gi0